Evidence map›Paper›PMID 41193205›Full record

ArticleBMJ open2025

Implementation strategy for an antibiotic stewardship bundle to promote optimal treatment choices in neonates with suspected early-onset sepsis (Protect-Neo): a study protocol for a multicentre, prospective interrupted time series and before-after study.

Liesanne E J van Veen, Gerdien A Tramper-Stranders, Niek B Achten, Frans B Plötz, Annemarie M C van Rossum, Erwin Ista

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06845332 (PROTeCt-NEO), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06845332 recruitingnot on this map

PROTeCt-NEO: Promoting Optimal Treatment Choices Through Implementation of Antibiotic Stewardship Strategies in Neonates With Suspected Early-Onset Sepsis

TypeobservationalSponsorFranciscus GasthuisRan2024 to 2026Enrolled55,000ConditionsEarly-onset Sepsis
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Liesanne E J van VeenDepartment of Paediatrics, Franciscus Gasthuis, Rotterdam, The Netherlands g.tramper@franciscus.nl l.vanveen@franciscus.nl.ORCID http://orcid.org/0009-0000-1377-7992
Gerdien A Tramper-StrandersDepartment of Paediatrics, Franciscus Gasthuis, Rotterdam, The Netherlands g.tramper@franciscus.nl l.vanveen@franciscus.nl.ORCID http://orcid.org/0000-0002-0228-5375
Niek B AchtenDepartment of Paediatrics, Sophia Children Hospital, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-0286-4393
Frans B PlötzDepartment of Paediatrics, Tergooi Medical Centre, Hilversum, The Netherlands.ORCID http://orcid.org/0000-0003-3212-2048
Annemarie M C van RossumDepartment of Paediatrics, Sophia Children Hospital, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1259-477X
Erwin IstaDepartment of Internal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-1257-3108

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral antibiotic stewardship interventions have been proven effective and safe for reducing the high number of antibiotic prescriptions in late preterm and term neonates at risk of early-onset sepsis (EOS). For successful translation of EOS interventions to clinical practice, implementation strategies should be employed targeting stakeholders. The primary aim of this study is to assess the impact of implementing an antibiotic stewardship bundle, including the EOS calculator, procalcitonin-guided therapy and intravenous-to-oral switch therapy on antibiotic exposure for EOS in Dutch secondary hospitals. Secondary aims are to examine additional clinical outcomes and implementation outcomes. METHODS AND ANALYSIS: We will conduct a multicentre, prospective implementation study with interrupted time series and before-after analyses at the paediatric or specialised neonatal departments of 11 Dutch secondary hospitals and their surrounding neonatal care networks. A multimodal implementation strategy, designed using Implementation Mapping, is employed to facilitate implementation. The study population is twofold: (1) neonates born at 34 weeks of gestation or later with suspected EOS that will receive intervention-related care and (2) paediatricians, paediatric residents, neonatal nurses, maternity nurses and parents who are the focus of the implementation strategies. The primary outcome is days of antibiotic therapy per 1000 live-born neonates, which will be evaluated using interrupted time series analysis as well as before-after comparison. Secondary clinical outcomes will be assessed by comparing clinical data from the 12 months pre-implementation and post implementation. Implementation outcomes are adoption, fidelity, feasibility and acceptability of the interventions and fidelity and appropriateness of the implementation strategies. Implementation outcomes will be assessed using both qualitative and quantitative methods, including surveys, individual interviews and focus group interviews. A mixed-methods approach will be used to integrate clinical and implementation outcomes. ETHICS AND DISSEMINATION: The Medical Ethics Committee United (MEC-U) declared (reference: W24.132) that this study does not fall under the Dutch Medical Research Involving Human Subjects Act (WMO). Subsequently, ethical approval was granted by the Scientific Committee of the Franciscus Hospital (T110). The scientific committees of all participating sites adopted this decision and granted permission for local conduct of the study. As electronic health record data are sampled retrospectively and anonymously, a waiver of consent was given to collect these data. Informed consent will be obtained from participants completing surveys or taking part in interviews and focus group discussions. The findings will be disseminated through journal publications and conference presentations. Furthermore, practice and policy recommendations will be collaboratively developed with partner organisations. TRIAL REGISTRATION NUMBER: NCT06845332.

Indexed as

Anti-Bacterial AgentsAntimicrobial StewardshipNeonatal SepsisSepsisControlled Before-After StudiesHumansInfant, NewbornInterrupted Time Series AnalysisMulticenter Studies as TopicNetherlandsProspective StudiesAnti-Bacterial AgentsAntibioticsINFECTIOUS DISEASESNEONATOLOGYSepsis

Identifiers

PMID41193205
PMCPMC12588035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.